Etienne Mouisel

Etienne Mouisel

Auto-generated profile, based on publicly available information

Etienne Mouisel

Universite de Toulouse, Inserm, Institut des Maladies Metaboliques et Cardiovasculaires (I2MC), UMR1297, Toulouse, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2013 in Nature Genetics
Verified
Journal Article
Closed access
RSRoberta Sartori
Roberta Sartori
ESElija Schirwis
Elija Schirwis
BBBert Blaauw
Bert Blaauw
SBSergia Bortolanza
Sergia Bortolanza
JZJinghui Zhao
Jinghui Zhao
MSMarco Sandri
Marco Sandri

1 June 2016 in Biochimie
Verified
Journal Article
Closed access
PMPauline Morigny
Pauline Morigny
MHMarianne Houssier
Marianne Houssier
EMEtienne Mouisel
Etienne Mouisel
DLDominique Langin
Dominique Langin

30 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CVClaire Vinel
Claire Vinel
LLLaura Lukjanenko
Laura Lukjanenko
ABAurelie Batut
Aurelie Batut
SDSimon Deleruyelle
Simon Deleruyelle
JPJean-Philippe Pradère
Jean-Philippe Pradère
CDCedric Dray
Cedric Dray

19 February 2013 in PLOS Biology
Verified
Journal Article
Open access
PDF file
AGAmandine Girousse
Amandine Girousse
GTGeneviève Tavernier
Geneviève Tavernier
CVCarine Valle
Carine Valle
CMCedric Moro
Cedric Moro
NMNiklas Mejhert
Niklas Mejhert
DLDominique Langin
Dominique Langin
When energy is needed, white adipose tissue (WAT) provides fatty acids (FAs) for use in peripheral tissues via stimulation of fat cell lipolysis. FAs have been postulated to play a critical role in the development of obesity-induced insulin resistance, a major risk factor for diabetes and cardiovascular disease. However, whether and how chronic inhibition of fat mobilization from WAT modulates insulin sensitivity remains elusive. Hormone-sensitive lipase (HSL) participates in the breakdown of WAT triacylglycerol into FAs. HSL haploinsufficiency and treatment with a HSL inhibitor resulted in improvement of insulin tolerance without impact on body weight, fat mass, and WAT inflammation in high-fat-diet–fed mice. In vivo palmitate turnover analysis revealed that blunted lipolytic capacity is associated with diminution in FA uptake and storage in peripheral tissues of obese HSL haploinsufficient mice. The reduction in FA turnover was accompanied by an improvement of glucose metabolism with a shift in respiratory quotient, increase of glucose uptake in WAT and skeletal muscle, and enhancement of de novo lipogenesis and insulin signalling in liver. In human adipocytes, HSL gene silencing led to improved insulin-stimulated glucose uptake, resulting in increased de novo lipogenesis and activation of cognate gene expression. In clinical studies, WAT lipolytic rate was positively and negatively correlated with indexes of insulin resistance and WAT de novo lipogenesis gene expression, respectively. In obese individuals, chronic inhibition of lipolysis resulted in induction of WAT de novo lipogenesis gene expression. Thus, reduction in WAT lipolysis reshapes FA fluxes without increase of fat mass and improves glucose metabolism through cell-autonomous induction of fat cell de novo lipogenesis, which contributes to improved insulin sensitivity. In periods of energy demand, mobilization of fat stores in mammals (i.e., adipose tissue lipolysis) is essential to provide energy in the form of fatty acids. In excess, however, fatty acids induce resistance to the action of insulin, which serves to regulate glucose metabolism in skeletal muscle and liver. Insulin resistance (or low insulin sensitivity) is believed to be a cornerstone of the complications of obesity such as type 2 diabetes and cardiovascular diseases. In this study, our clinical observation of natural variation in fat cell lipolysis in individuals reveals that a high lipolytic rate is associated with low insulin sensitivity. Furthermore, partial genetic and pharmacologic inhibition of hormone-sensitive lipase, one of the enzymes involved in the breakdown of white adipose tissue lipids, results in improvement of insulin sensitivity in mice without gain in body weight and fat mass. We undertake a series of mechanistic studies in mice and in human fat cells to show that blunted lipolytic capacity increases the synthesis of new fatty acids from glucose in fat cells, a pathway that has recently been shown by others to be a major determinant of whole body insulin sensitivity. In conclusion, partial inhibition of adipose tissue lipolysis is a plausible strategy in the treatment of obesity-related insulin resistance.

13 November 2006 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ATAnne Tarrade
Anne Tarrade
CFCoralie Fassier
Coralie Fassier
SCSabrina Courageot
Sabrina Courageot
DCDelphine Charvin
Delphine Charvin
Jeremie VitteJeremie Vitte
Jeremie Vitte
JMJudith Melki
Judith Melki
Mutations of the spastin gene (Sp) are responsible for the most frequent autosomal dominant form of spastic paraplegia, a disease characterized by the degeneration of corticospinal tracts. We show that a deletion in the mouse Sp gene, generating a premature stop codon, is responsible for progressive axonal degeneration, restricted to the central nervous system, leading to a late and mild motor defect. The degenerative process is characterized by focal axonal swellings, associated with abnormal accumulation of organelles and cytoskeletal components. In culture, mutant cortical neurons showed normal viability and neurite density. However, they develop neurite swellings associated with focal impairment of retrograde transport. These defects occur near the growth cone, in a region characterized by the transition between stable microtubules rich in detyrosinated α-tubulin and dynamic microtubules composed almost exclusively of tyrosinated α-tubulin. Here, we show that the Sp mutation has a major impact on neurite maintenance and transport both in vivo and in vitro. These results highlight the link between spastin and microtubule dynamics in axons, but not in other neuronal compartments. In addition, it is the first description of a human neurodegenerative disease which involves this specialized region of the axon.

5 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HAHelge Amthor
Helge Amthor
AOAnthony Otto
Anthony Otto
AVAdeline Vulin
Adeline Vulin
ARAnne Rochat
Anne Rochat
JDJulie Dumonceaux
Julie Dumonceaux
TPTerence Partridge
Terence Partridge
Myostatin, a member of the TGF-β family, has been identified as a powerful inhibitor of muscle growth. Absence or blockade of myostatin induces massive skeletal muscle hypertrophy that is widely attributed to proliferation of the population of muscle fiber-associated satellite cells that have been identified as the principle source of new muscle tissue during growth and regeneration. Postnatal blockade of myostatin has been proposed as a basis for therapeutic strategies to combat muscle loss in genetic and acquired myopathies. But this approach, according to the accepted mechanism, would raise the threat of premature exhaustion of the pool of satellite cells and eventual failure of muscle regeneration. Here, we show that hypertrophy in the absence of myostatin involves little or no input from satellite cells. Hypertrophic fibers contain no more myonuclei or satellite cells and myostatin had no significant effect on satellite cell proliferation in vitro, while expression of myostatin receptors dropped to the limits of detectability in postnatal satellite cells. Moreover, hypertrophy of dystrophic muscle arising from myostatin blockade was achieved without any apparent enhancement of contribution of myonuclei from satellite cells. These findings contradict the accepted model of myostatin-based control of size of postnatal muscle and reorient fundamental investigations away from the mechanisms that control satellite cell proliferation and toward those that increase myonuclear domain, by modulating synthesis and turnover of structural muscle fiber proteins. It predicts too that any benefits of myostatin blockade in chronic myopathies are unlikely to impose any extra stress on the satellite cells.